Triple
T1169593
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Ionis Pharmaceuticals |
E24882
|
entity |
| Predicate | hasCollaborationWith |
P398
|
FINISHED |
| Object | Biogen |
E3807
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Biogen | Statement: [Ionis Pharmaceuticals, hasCollaborationWith, Biogen]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Biogen Context triple: [Ionis Pharmaceuticals, hasCollaborationWith, Biogen]
-
A.
Biogen
chosen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
B.
Eisai and Biogen
Eisai and Biogen are pharmaceutical companies that collaborate on developing innovative therapies, particularly in the field of neurodegenerative diseases such as Alzheimer’s.
-
C.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
D.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
E.
Eli Lilly and Company
Eli Lilly and Company is a major American pharmaceutical corporation known for developing and manufacturing a wide range of prescription medicines, including treatments for diabetes, cancer, and mental health disorders.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: hasCollaborationWith Context triple: [Ionis Pharmaceuticals, hasCollaborationWith, Biogen]
-
A.
hasCoauthor
Indicates that two or more entities have jointly authored the same work or publication.
-
B.
notableCollaboration
Indicates a significant joint effort or partnership between entities that produced a noteworthy shared outcome or work.
-
C.
coDirectedWith
Indicates that two or more entities jointly directed the same work or project.
-
D.
worksWith
chosen
Indicates that two entities collaborate or perform tasks together in a shared work-related context.
-
E.
isCollaboration
Indicates that two or more entities are jointly working together toward a shared goal or producing something in partnership.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a494082a7c819095004f423f294a64 |
completed | March 1, 2026, 7:31 p.m. |
| NER | Named-entity recognition | batch_69a4bce821b481908bc278a3fa7973f4 |
completed | March 1, 2026, 10:25 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ac8f6d4e788190b993dc2bdd69ed26 |
completed | March 7, 2026, 8:49 p.m. |
| PD | Predicate disambiguation | batch_69a4bb5656948190b0b1d5446ad06005 |
completed | March 1, 2026, 10:19 p.m. |
Created at: March 1, 2026, 7:45 p.m.